Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Type-1 Polarized Dendritic Cell-induced Antigen-specific Autologous Cytotoxic T Lymphocytes

Known as: Autologous DC1-CTL, DC1-induced Antigen-specific Autologous CTLs, Type-1 Polarized DC-induced Antigen-specific Autologous CTLs 
A preparation of autologous cytotoxic T-lymphocytes (CTL), specifically reactive to melanoma-associated antigen 3 (MAGE-3), MAGE-4, survivin, human… Expand
National Institutes of Health

Related topics

Related topics

4 relations
Antigen SensitizationCytotoxic T-LymphocytesT-Cell Activationimmunopotentiation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer
Inhibitors against the p110δ isoform of phosphoinositide-3-OH kinase (PI(3)K) have shown remarkable therapeutic efficacy in some… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma1
A variety of cancers, including malignant gliomas, show aberrant activation of STAT3, which plays a pivotal role in negative… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2002
Highly Cited
2002
Identification of HLA-A2–restricted CD8+ Cytotoxic T Cell Responses in Primary Biliary Cirrhosis
Primary biliary cirrhosis (PBC) is characterized by an intense biliary inflammatory CD4+ and CD8+ T cell response. Very limited… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2001
Highly Cited
2001
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
The epithelial mucin MUC1 is overexpressed on the cell surface of many epithelial malignancies as well as on some B-cell… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
1999
Highly Cited
1999
Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf) and Cd40 Ligand Genes Take up and Present Endogenous Tumor-Associated Antigens, and…
We transduced BALB/c-derived C-26 colon carcinoma cells with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40… Expand
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 4
Highly Cited
1999
Highly Cited
1999
A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia
Human minor histocompatibility antigens (mHags) play an important role in the induction of cytotoxic T lymphocyte (CTL… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 5
  • figure 4
Highly Cited
1999
Highly Cited
1999
Feasibility of Immunotherapy of Relapsed Leukemia With Ex Vivo–Generated Cytotoxic T Lymphocytes Specific for Hematopoietic System-Restricted Minor Histocompatibility Antigens
Allogeneic bone marrow transplantation (BMT) is a common treatment of hematologic malignancies. Recurrence of the underlying… Expand
Highly Cited
1999
Highly Cited
1999
Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
Allogeneic bone marrow transplantation (BMT) is a common treatment of hematologic malignancies. Recurrence of the underlying… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1998
Highly Cited
1998
High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo
Vitiligo is an autoimmune condition characterized by loss of epidermal melanocytes. Using tetrameric complexes of human… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
1998
Highly Cited
1998
Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
Sixteen metastatic breast cancer patients were immunized with a low dose (5 μg) of a 16 amino acid MUC1 peptide (GVTSAPDTRPAPGSTA… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE